{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:40:32Z","timestamp":1781163632594,"version":"3.54.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["2023080955F \u2013 00"],"award-info":[{"award-number":["2023080955F \u2013 00"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec015\">\n<jats:title>Background<\/jats:title>\n<jats:p>The prices of generic drugs in general are known to be higher in Korea than in other countries. However, it remains unknown whether the price levels of generic drugs in Korea relative to other countries can differ by therapeutic class. Therefore, this study compared the prices of generic drugs in four commonly used drug classes in Korea with those in other high-income countries.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec016\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Using IQVIA\u2019s Pricing Insight data from 2018 to 2022, we calculated the Laspeyres price index for generic drugs in four therapeutic classes (antidiabetic drugs, lipid-modifying agents, antihypertensive drugs, and antibiotics). We selected eight high-income countries, such as Canada, France, Germany, Italy, Japan, Switzerland, the United Kingdom, and the United States, for comparison and Korea as the base country. Price to chemist was used and the currency conversion was based on the exchange rate and the purchasing power parity.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec017\">\n<jats:title>Results<\/jats:title>\n<jats:p>Prices of generic drugs are lower in all of comparison countries combined than in Korea for lipid-modifying drugs and antihypertensive drugs. For these two drug classes, all countries but the U.S. have the index lower than one. The index for antidiabetic drugs was less than one in all countries except for Canada and the U.S. For antibiotics, all countries but France, Italy, and Japan have the index that is greater than one. Furthermore, the price index for generic antibiotics increased from 2018 to 2022 in all countries but Canada and Japan.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec018\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The prices of generic drugs are higher in Korea than in other high-income countries for lipid-modifying agents and antihypertensive drugs. The prices of generic antibiotics are higher in many comparison countries and have further increased from 2018 to 2021.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0319674","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T17:41:03Z","timestamp":1741714863000},"page":"e0319674","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-4174","authenticated-orcid":true,"given":"Chanmi","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-6617","authenticated-orcid":true,"given":"Inmyung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"3","key":"pone.0319674.ref001","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/1468-0009.12279","article-title":"Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending","volume":"95","author":"OJ Wouters","year":"2017","journal-title":"Milbank Q"},{"issue":"6","key":"pone.0319674.ref002","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jsps.2013.12.017","article-title":"The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use","volume":"22","author":"MA Hassali","year":"2014","journal-title":"Saudi Pharm J"},{"issue":"3","key":"pone.0319674.ref003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.17480\/psk.2023.67.3.205","article-title":"Trends in Pharmaceutical Market Structure and Generic Drug Utilization in the Korean National Health Security System (2007-2017)","volume":"67","author":"S Jang","year":"2023","journal-title":"Yakhak Hoeji"},{"issue":"3","key":"pone.0319674.ref004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.healthpol.2013.08.011","article-title":"Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents","volume":"112","author":"H-Y Kwon","year":"2013","journal-title":"Health Policy"},{"issue":"1","key":"pone.0319674.ref005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12913-017-2555-y","article-title":"Perception and attitude of Korean physicians towards generic drugs","volume":"17","author":"M Ryu","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"pone.0319674.ref006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.healthpol.2018.11.002","article-title":"Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea","volume":"123","author":"H-Y Kwon","year":"2019","journal-title":"Health Policy"},{"issue":"2","key":"pone.0319674.ref007","doi-asserted-by":"crossref","first-page":"110","DOI":"10.17480\/psk.2022.66.2.110","article-title":"Changes in Drug Listing Trends after the Reform of the Off-patent Pharmaceutical Pricing System in National Health Insurance","volume":"66","author":"H-J Lee","year":"2022","journal-title":"Yakhak Hoeji"},{"key":"pone.0319674.ref008","article-title":"International prescription drug price comparisons","author":"A Mulcahy","year":"2021"},{"issue":"1","key":"pone.0319674.ref009","first-page":"46","article-title":"International drug price comparisons: quality assessment","volume":"29","author":"M Machado","year":"2011","journal-title":"Rev Panam Salud Publica"},{"issue":"3","key":"pone.0319674.ref010","first-page":"41","article-title":"International comparison of generic medicine prices","volume":"16","author":"S Kim","year":"2010","journal-title":"The Korean Journal of Health Economics and Policy"},{"issue":"2","key":"pone.0319674.ref011","first-page":"49","article-title":"The cross-national drug price comparison depending on the methods","volume":"27","author":"E-M Bae","year":"2021","journal-title":"The Korean Journal of Health Economics and Policy"},{"issue":"Suppl 1","key":"pone.0319674.ref012","first-page":"S5-11","article-title":"Definition and Classification of Generic Drugs Across the World","volume":"13","author":"R Alfonso-Cristancho","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"pone.0319674.ref013","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0168-8510(00)00061-0","article-title":"A comparative analysis of generics markets in five European countries","volume":"51","author":"L Garattini","year":"2000","journal-title":"Health Policy"},{"key":"pone.0319674.ref014","year":"2024"},{"key":"pone.0319674.ref015","volume-title":"Foreign Drug Price Comparative Reevaluation, Korean Government Draft Released","author":"Dailypharm","year":"2024"},{"issue":"7","key":"pone.0319674.ref016","doi-asserted-by":"crossref","first-page":"e046917","DOI":"10.1136\/bmjopen-2020-046917","article-title":"Determinants of drug prices: a systematic review of comparison studies","volume":"11","author":"JM Janssen Daalen","year":"2021","journal-title":"BMJ Open"},{"issue":"11","key":"pone.0319674.ref017","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1185\/030079907X233395","article-title":"International comparison of generic medicine prices","volume":"23","author":"S Simoens","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"pone.0319674.ref018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev-publhealth-040119-094305","article-title":"Comparative Approaches to Drug Pricing","volume":"41","author":"S-Y Kang","year":"2020","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"pone.0319674.ref019","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13561-020-00289-6","article-title":"Is greater generic competition also linked to lower drug prices in South Korea?","volume":"10","author":"K-B Son","year":"2020","journal-title":"Health Econ Rev"},{"issue":"3","key":"pone.0319674.ref020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/M16-1432","article-title":"High Generic Drug Prices and Market Competition: A Retrospective Cohort Study","volume":"167","author":"CV Dave","year":"2017","journal-title":"Ann Intern Med"},{"issue":"10","key":"pone.0319674.ref021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/11585970-000000000-00000","article-title":"Does the market share of generic medicines influence the price level?: a European analysis","volume":"29","author":"P Dylst","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"pone.0319674.ref022","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/ph3030471","article-title":"Generic Medicine Pricing Policies in Europe: Current Status and Impact","volume":"3","author":"P Dylst","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"pone.0319674.ref023","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/cix634","article-title":"Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States","volume":"65","author":"JD Alpern","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pone.0319674.ref024","doi-asserted-by":"crossref","first-page":"113321","DOI":"10.1016\/j.jpeds.2023.01.001","article-title":"The Shortage of Amoxicillin: An Escalating Public Health Crisis in Pediatrics Faced by Several Western Countries","volume":"257","author":"R Cohen","year":"2023","journal-title":"J Pediatr"},{"issue":"3","key":"pone.0319674.ref025","doi-asserted-by":"crossref","first-page":"E535","DOI":"10.9778\/cmajo.20200036","article-title":"Factors associated with drug shortages in Canada: a retrospective cohort study","volume":"8","author":"W Zhang","year":"2020","journal-title":"CMAJ Open"},{"issue":"11","key":"pone.0319674.ref026","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jval.2018.04.1826","article-title":"Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study","volume":"21","author":"CV Dave","year":"2018","journal-title":"Value Health"},{"key":"pone.0319674.ref027","doi-asserted-by":"crossref","first-page":"108258","DOI":"10.1016\/j.cie.2022.108258","article-title":"Pharmaceutical supply chain reliability and effects on drug shortages","volume":"169","author":"EL Tucker","year":"2022","journal-title":"Computers & Industrial Engineering"},{"key":"pone.0319674.ref028","doi-asserted-by":"crossref","first-page":"582154","DOI":"10.3389\/fphar.2020.582154","article-title":"Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications","volume":"11","author":"M Haque","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0319674.ref029","doi-asserted-by":"crossref","first-page":"585832","DOI":"10.3389\/fpubh.2020.585832","article-title":"Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future","volume":"8","author":"B Godman","year":"2020","journal-title":"Front Public Health"},{"issue":"9","key":"pone.0319674.ref030","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jama.2019.20504","article-title":"Drug Shortages in the United States: Are Some Prices Too Low?","volume":"323","author":"I Hernandez","year":"2020","journal-title":"JAMA"},{"issue":"16","key":"pone.0319674.ref031","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40265-016-0651-7","article-title":"The Impact of Shortages on Medication Prices: Implications for Shortage Prevention","volume":"76","author":"M Alevizakos","year":"2016","journal-title":"Drugs"},{"key":"pone.0319674.ref032","volume-title":"Price increases for prescription drugs, 2016\u20132022","author":"A Bosworth","year":"2022"},{"key":"pone.0319674.ref033","doi-asserted-by":"crossref","first-page":"1185356","DOI":"10.3389\/fpubh.2023.1185356","article-title":"The impact of drug shortages on drug prices: evidence from China","volume":"11","author":"S Hu","year":"2023","journal-title":"Front Public Health"},{"issue":"4","key":"pone.0319674.ref034","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40258-017-0307-0","article-title":"Drug Pricing in South Korea","volume":"15","author":"H-Y Kwon","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"pone.0319674.ref035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12913-017-2184-5","article-title":"A comparison of generic drug prices in seven European countries: a methodological analysis","volume":"17","author":"OJ Wouters","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"Suppl 1","key":"pone.0319674.ref036","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00019053-199814001-00014","article-title":"International price comparisons for pharmaceuticals. Measurement and policy issues","volume":"14","author":"PM Danzon","year":"1998","journal-title":"Pharmacoeconomics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T17:41:18Z","timestamp":1741714878000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319674"}},"subtitle":[],"editor":[{"given":"Ebenezer","family":"Wiafe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0319674","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}